Insulin Lispro: Uses, Mechanism, and Side Effects

Managing blood glucose day to day often comes down to how quickly and predictably an insulin works. Insulin lispro is a rapid-acting insulin analog designed to address that need in people living with diabetes mellitus.

Key takeaways

• Insulin lispro is a rapid-acting human insulin analog marketed under the brand name ADMELOG.
• It is approved to improve glycemic control in both adult and pediatric patients with diabetes mellitus.
• The label carries no boxed warning.
• More than 380 registered trials have studied insulin lispro, including head-to-head comparisons with other insulin products.
• FAERS reports are dominated by blood glucose fluctuations, dosing errors, and gastrointestinal or general symptoms.

What Insulin Lispro Is

Insulin lispro belongs to the insulin analog drug class. It works the way natural insulin does: by helping skeletal muscle and fat tissue take up glucose from the blood while reducing the liver's own glucose output. The hormone also slows the breakdown of fat and protein and supports protein synthesis, which together help regulate overall metabolism.

What Insulin Lispro Is Approved For

Under the brand name ADMELOG, insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. As a rapid-acting formulation, it is positioned within the broader insulin treatment landscape rather than as a long-acting background option. The label does not carry a boxed warning.

What the Evidence Shows

Insulin lispro has been studied in 387 registered clinical trials. One completed phase 2 trial compared the pharmacokinetics and pharmacodynamics of insulin lispro delivered into different tissues in people with type 1 diabetes mellitus. A separate completed phase 1 trial assessed the efficacy and safety of a combination insulin lispro mix against another marketed mix product in type 1 diabetes patients. A phase 3 trial of unknown status is also examining glucose control through a bihormonal artificial pancreas system following total pancreatectomy.

Reported Side Effects

FAERS reports for insulin lispro, which reflect reported events rather than confirmed incidence or causation, most frequently involve blood glucose abnormalities. Blood glucose increased was the single most reported term (39,590 reports), alongside blood glucose decreased (8,989) and drug ineffective (8,466). Dosing issues also feature prominently, with incorrect dose administered reported 9,670 times. Other frequently reported terms include visual impairment (5,685), nausea (5,078), malaise (4,085), and fatigue (3,952).